Treos Bio Announces Presentation of Final Results from Phase 1b Study of PolyPEPI1018 Immunotherapy for Late-Stage Metastatic Colorectal Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
PolyPEPI1018 is an off-the-shelf, multi-peptide vaccine derived from seven tumor associated antigens frequently expressed in patients with mCRC.
- PolyPEPI1018 is an off-the-shelf, multi-peptide vaccine derived from seven tumor associated antigens frequently expressed in patients with mCRC.
- Final results from the study, conducted by Mayo Clinic in Minnesota, demonstrate that PolyPEPI1018 in combination with TAS-102 improved progression free-survival (PFS) and overall survival (OS) compared to historical data for standard of care TAS-102 alone.
- “Importantly, these results show consistency between immunological responses and efficacy, and a particularly enhanced benefit in patients without liver metastasis.
- Final results from the study demonstrate that PolyPEPI1018 and TAS-102 were safe and tolerable in combination with safety and toxicity profiles similar to TAS-102 monotherapy.